Verve Therapeutics Inc (VERV)
4.595
+0.04
(+0.99%)
USD |
NASDAQ |
Nov 21, 16:00
4.595
0.00 (0.00%)
After-Hours: 20:00
Verve Therapeutics Revenue (Quarterly): 6.865M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 6.865M |
| June 30, 2024 | 6.692M |
| March 31, 2024 | 5.695M |
| December 31, 2023 | 5.144M |
| September 30, 2023 | 3.117M |
| Date | Value |
|---|---|
| June 30, 2023 | 2.093M |
| March 31, 2023 | 1.404M |
| December 31, 2022 | 1.012M |
| September 30, 2022 | 0.929M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.929M
Minimum
Sep 2022
6.865M
Maximum
Sep 2024
3.661M
Average
3.117M
Median
Sep 2023
Revenue (Quarterly) Benchmarks
| Ardelyx Inc | 98.24M |
| Biomarin Pharmaceutical Inc | 745.74M |
| Sage Therapeutics Inc | 11.87M |
| ALX Oncology Holdings Inc | -- |
| Immuneering Corp | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -50.13M |
| Total Expenses (Quarterly) | 63.78M |
| EPS Diluted (Quarterly) | -0.59 |
| Enterprise Value | -154.70M |
| Profit Margin (Quarterly) | -730.3% |
| Earnings Yield | -53.54% |
| Normalized Earnings Yield | -53.54 |